MedPath
Found 988 clinical trials|View Analysis
Sort by:

Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia

Recruiting
Conditions
Systemic Lupus Erythematosus
First Posted Date
2025-01-06
Last Posted Date
2025-01-06
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT06759519
Locations
🇷🇺

Research Site, Volgograd, Russian Federation

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Refractory Systemic Lupus Erythematosus (GALLOP)

Phase 1
Not yet recruiting
Conditions
Systemic Lupus Erythematosus
Lupus
Lupus Erythematosus
Lupus Nephritis
Interventions
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
Caribou Biosciences, Inc.
Target Recruit Count
20
Registration Number
NCT06752876

UC-MSC Cell Therapy Study for SLE Patients

Phase 1
Not yet recruiting
Conditions
SLE
Lupus
Systemic Lupus Erthematosus
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Interventions
Diagnostic Test: Physical examination
Diagnostic Test: Electrocardiogram
Other: SF-36 questionnaire
Diagnostic Test: Clinical laboratory evaluations - Serology
Diagnostic Test: Clinical laboratory evaluations - Biochemistry
Diagnostic Test: Clinical laboratory evaluations - Hematology
Diagnostic Test: Pregnancy Test
Diagnostic Test: Urinalysis
Diagnostic Test: SLE activity evaluation
Diagnostic Test: SLE biomarker profiling
Diagnostic Test: Cytokines and chemokine profiling
Biological: single dose of UC-MSCs
First Posted Date
2024-12-17
Last Posted Date
2024-12-27
Lead Sponsor
LiveKidney.Bio
Target Recruit Count
10
Registration Number
NCT06737380
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

Not Applicable
Not yet recruiting
Conditions
Systemic Lupus Erythematosus (SLE)
First Posted Date
2024-12-06
Last Posted Date
2024-12-19
Lead Sponsor
Duke University
Target Recruit Count
40
Registration Number
NCT06720584
Locations
🇺🇸

Duke University, Durham, North Carolina, United States

Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These Patients

Recruiting
Conditions
Juvenile Systemic Lupus Erythematosus
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Sohag University
Target Recruit Count
50
Registration Number
NCT06718283
Locations
🇪🇬

Faculty of medicine, Sohag, Egypt

Interleukin23 in Systemic Lupus

Not Applicable
Recruiting
Conditions
Systemic Lupus Erythematosus Related Interstial Lung Disease
Interventions
Biological: interleukin 23
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
Sohag University
Target Recruit Count
90
Registration Number
NCT06713187
Locations
🇪🇬

Sohag university hospital, Sohag, Egypt

🇪🇬

Sohag university, Sohag, Egypt

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

Early Phase 1
Recruiting
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Metabolically Armed CD19 CAR-T cells
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Zhejiang University
Target Recruit Count
36
Registration Number
NCT06711146
Locations
🇨🇳

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

Phase 1
Not yet recruiting
Conditions
Systemic Lupus Erythematous (SLE)
Interventions
Biological: CD19 CAR-T cells
First Posted Date
2024-11-28
Last Posted Date
2024-11-28
Lead Sponsor
National University of Malaysia
Target Recruit Count
5
Registration Number
NCT06710717
Locations
🇲🇾

University Kebangsaan Malaysia Medical Center, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia

US Zamto-cel Autoimmune Diseases

Phase 1
Not yet recruiting
Conditions
Lupus Nephritis
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Interventions
Biological: zamtocabtagene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Miltenyi Biomedicine GmbH
Target Recruit Count
48
Registration Number
NCT06708845

This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE

Recruiting
Conditions
Systemic Lupus Erythematosus
First Posted Date
2024-11-21
Last Posted Date
2024-12-12
Lead Sponsor
AstraZeneca
Target Recruit Count
1000
Registration Number
NCT06698900
Locations
🇧🇷

Research Site, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath